Immunocore Holdings (IMCR) Income towards Parent Company (2021 - 2026)
Immunocore Holdings (IMCR) posted Income towards Parent Company of $13.0 million for Q1 2026, up 143.15% sequentially from -$30.1 million in Q4 2025, and up 160.25% YoY from $5.0 million in Q1 2025.
Analysis
Immunocore Holdings (IMCR) Income towards Parent Company (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Income towards Parent Company for 6 years, with the latest figure at $13.0 million in Q1 2026.
- Quarterly Income towards Parent Company rose 160.25% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (down 27.23% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
- Income towards Parent Company grew to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $13.0 million in Q1 2026 and troughed at -$30.1 million in Q4 2025.
- A 5-year average of -$10.7 million and a median of -$14.6 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company jumped 864.24% in 2024, then plunged 102.24% in 2025.
- Over 5 years, Income towards Parent Company stood at -$29.9 million in 2022, then jumped by 33.95% to -$19.7 million in 2023, then fell by 20.48% to -$23.8 million in 2024, then retreated by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $13.0 million, -$30.1 million, and -$196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 971.91 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -814,000.00 |
| Mar 31, 2026 | 12.97 Mn |
| Dec 31, 2025 | -30.06 Mn |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | -23.77 Mn |
| Sep 30, 2024 | 8.74 Mn |
| Jun 30, 2024 | -11.63 Mn |
| Mar 31, 2024 | -24.48 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | 906,000.00 |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -29.56 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | -19.69 Mn |
| Dec 31, 2021 | -53.10 Mn |
| Sep 30, 2021 | -41.54 Mn |